PainReform LtdNASDAQ:PRFX
- LAST PRICE0.8570
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.8566/ 2
- Ask / Lots0.8700/ 6
- Open / Previous Close0.0000 / 0.8570
- Day Range---
- 52 Week Range
- Volume70
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRFX |
|---|---|---|
| 09:32 ET | 978 | 0.852 |
| 09:34 ET | 112 | 0.84 |
| 10:30 ET | 2150 | 0.84 |
| 11:31 ET | 600 | 0.8399 |
| 11:33 ET | 100 | 0.84 |
| 12:23 ET | 1200 | 0.84 |
| 12:48 ET | 880 | 0.84 |
| 12:59 ET | 3399 | 0.841 |
| 01:33 ET | 1306 | 0.8401 |
| 02:15 ET | 600 | 0.8695 |
| 02:33 ET | 100 | 0.831 |
| 03:23 ET | 4277 | 0.8274 |
| 03:48 ET | 361 | 0.8274 |
| 03:59 ET | 308 | 0.857 |
Apr 18, 2024
PainReform Announces Closing of $4 Million Public Offering, from 2:19PM ET on Thursday Apr 18, 2024 by Dow Jones
2:19PM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 16, 2024
PainReform Announces Pricing of $4 Million Public Offering, from 8:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 16, 2024 by Dow JonesPress Release: PainReform Announces Pricing of $4 Million Public Offering, from 8:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 9, 2024
Apr 2, 2024
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy, from 8:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PainReform Ltd | 2.1M | -0.1x | --- |
Vestiage Inc | 1.2M | 2.5x | --- |
Lucy Scientific Discovery Inc | 1.6M | -0.1x | --- |
Link Reservations Inc | 1.6M | 0.0x | --- |
Nexien Biopharma Inc | 1.4M | -4.9x | --- |
Nunzia Pharmaceutical Corp | 1.3M | 0.0x | --- |
Company Information
PAINREFORM LTD is a Israel-based pharmaceutical Company. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.
Contact Information
- Headquarters
- 65 Yigal Alon St.TEL AVIV-YAFO, Israel 6744316
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Ehud Geller
- Chief Executive Officer, Chief Financial Officer
- Ilan Hadar
- Chief Operating Officer
- Sigal Aviel
- Chief Technology Officer, Director
- Eli Hazum
- Vice President - Pharmaceutical Operations
- Rita Keynan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-7.21 |
Book Value | $4.19 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
